Australian drug development company NoxopharmTM to present interim results on new prostate cancer treatment at specialist oncology conferences in Australia and overseas
SYDNEY, 12 Sept 2019
NoxopharmTM Ltd (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today announced that scientific abstracts on interim data relating to its DARRT-1 prostate cancer treatment study have been accepted for inclusion in two major oncology conferences. These are clinical forums where all abstracts are peer reviewed by oncologists before being included in the program.
For further information please download the attached PDF:
Download this document